Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASAKBLF 93 EV-to-EBITDA is 20.78 as of Aug. 27, 2026, which is 46% below its 10-year median of 38.42. GuruFocus rates AKBLF with a GF Score™ of 93/100 and a GF Value™ of $38.95 (Fairly Valued). Among 414 Biotechnology companies, Alk-Abello AS ranks worse than 59.66% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alk-Abello AS's enterprise value is $7,078 Mil.
Alk-Abello AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $341 Mil. Therefore, Alk-Abello AS's EV-to-EBITDA for today is 20.78.
The historical rank and industry rank for Alk-Abello AS's EV-to-EBITDA or its related term are showing as below:
AKBLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.88 Med: 38.42 Max: 93.66
Current: 20.71
During the past 13 years, the highest EV-to-EBITDA of Alk-Abello AS was 93.66. The lowest was 9.88. And the median was 38.42.
AKBLF's EV-to-EBITDA is ranked worse than 59.66% of 414
companies
in the Biotechnology industry
Industry Median: 13.54
vs AKBLF: 20.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alk-Abello AS (OTCPK:AKBLF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alk-Abello AS's PE Ratio (TTM) for today is calculated as:
Alk-Abello AS's share price for today is $37.915.
Alk-Abello AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.948.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alk-Abello AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AKBLF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Alk-Abello AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's EV-to-EBITDA falls into.
Alk-Abello AS's current Enterprise Value is $7,078 Mil.
Alk-Abello AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $341 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (AKBLF) has a EV-to-EBITDA of 20.78 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alk-Abello AS. This is 46% below median its historical median of 38.42. Over the past decade, Alk-Abello AS's EV-to-EBITDA has ranged from 9.88 to 93.66. According to the industry distribution chart, Alk-Abello AS ranks #247 out of 414 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Alk-Abello AS's EV-to-EBITDA too high?
Alk-Abello AS's current EV-to-EBITDA of 20.78 is 46% below median its 10-year median of 38.42. Over the past 10 years, this metric has ranged from a low of 9.88 to a high of 93.66. The Biotechnology industry median EV-to-EBITDA is 13.54. Alk-Abello AS's value of 20.78 is 53.5% above this industry median. Based on the distribution chart, Alk-Abello AS ranks #247 out of 414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #247 out of 414 companies for EV-to-EBITDA. This places Alk-Abello AS in the lower half of its industry. The industry median EV-to-EBITDA is 13.54. Alk-Abello AS's value of 20.78 is 53.5% above this benchmark. Historically, Alk-Abello AS's own EV-to-EBITDA has ranged from 9.88 to 93.66 over the past decade. While the company's 10-year median is 38.42 vs. the industry median of 13.54, Alk-Abello AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.54, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current EV-to-EBITDA of 20.78 is 53.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alk-Abello AS. For the Biotechnology industry, the median EV-to-EBITDA is 13.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current EV-to-EBITDA is 20.78, which is 46% below median its own 10-year median of 38.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (AKBLF) is currently considered Fairly Valued. The stock's GF Value™ is $38.95, compared to a current price of $37.92 — trading 2.7% below its estimated fair value. The current EV-to-EBITDA is 20.78, which is 46% below median its 10-year median of 38.42 and 53.5% above the Biotechnology industry median of 13.54. Alk-Abello AS's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alk-Abello AS (AKBLF), the current EV-to-EBITDA is 20.78 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (AKBLF) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be undervalued.
The current stock price of $37.92 is trading 2.7% below its estimated GF Value™ of $38.95.
GuruFocus considers Alk-Abello AS to be Fairly Valued.
Key valuation signals for AKBLF:
EV-to-EBITDA: 20.78 (46% below median its 10-year median of 38.42)
GF Value™: $38.95 vs. price of $37.92 (2.7% below fair value)
Industry Position: 53.5% above the Biotechnology median (#247 of 414)
No single metric tells the full story. See the AKBLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
93GF Score
Get the complete analysis for AKBLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKBLF has been successfully added to your 
